Stock Track | Telix Pharmaceuticals Soars 7.58% Intraday on Major Regeneron Collaboration Deal

Stock Track

Apr 13

TELIX PHARMACEUTICALS LTD (TLX.AU) saw its stock price soar 7.58% during intraday trading on Monday, following a significant corporate announcement.

The sharp increase is attributed to the company's newly announced strategic collaboration with leading biotechnology firm Regeneron Pharmaceuticals. The agreement focuses on the co-development and co-commercialization of next-generation radiopharmaceutical therapies for oncology.

Under the terms of the deal, Telix will receive an upfront cash payment of US$40 million and is eligible for potential development and commercial milestone payments of up to US$2.1 billion, plus royalties on future net sales. The collaboration combines Telix's radiopharmaceutical development platform and manufacturing capabilities with Regeneron's extensive biologics expertise and antibody discovery technologies, operating on a 50/50 cost and profit-sharing model for initial programs.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/news/1158547007"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1158547007\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1158547007?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-04-13 08:04","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1158547007","market":"sg","top_or_hot":-1,"title":"Stock Track | Telix Pharmaceuticals Soars 7.58% Intraday on Major Regeneron Collaboration Deal","media":"Stock Track","content":"<p>TELIX PHARMACEUTICALS LTD (TLX.AU) saw its stock price soar 7.58% during intraday trading on Monday, following a significant corporate announcement.</p><p>The sharp increase is attributed to the company's newly announced strategic collaboration with leading biotechnology firm Regeneron Pharmaceuticals. The agreement focuses on the co-development and co-commercialization of next-generation radiopharmaceutical therapies for oncology.</p><p>Under the terms of the deal, Telix will receive an upfront cash payment of US$40 million and is eligible for potential development and commercial milestone payments of up to US$2.1 billion, plus royalties on future net sales. The collaboration combines Telix's radiopharmaceutical development platform and manufacturing capabilities with Regeneron's extensive biologics expertise and antibody discovery technologies, operating on a 50/50 cost and profit-sharing model for initial programs.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Telix Pharmaceuticals Soars 7.58% Intraday on Major Regeneron Collaboration Deal</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Telix Pharmaceuticals Soars 7.58% Intraday on Major Regeneron Collaboration Deal\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-04-13 08:04</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>TELIX PHARMACEUTICALS LTD (TLX.AU) saw its stock price soar 7.58% during intraday trading on Monday, following a significant corporate announcement.</p><p>The sharp increase is attributed to the company's newly announced strategic collaboration with leading biotechnology firm Regeneron Pharmaceuticals. The agreement focuses on the co-development and co-commercialization of next-generation radiopharmaceutical therapies for oncology.</p><p>Under the terms of the deal, Telix will receive an upfront cash payment of US$40 million and is eligible for potential development and commercial milestone payments of up to US$2.1 billion, plus royalties on future net sales. The collaboration combines Telix's radiopharmaceutical development platform and manufacturing capabilities with Regeneron's extensive biologics expertise and antibody discovery technologies, operating on a 50/50 cost and profit-sharing model for initial programs.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"TLX.AU","symbol_name":"TELIX PHARMACEUTICALS LTD","start_time":0,"source_url":"","article_id":"1158547007","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1158547007","pubTimestamp":1776038653,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"TELIX PHARMACEUTICALS LTD (TLX.AU) saw its stock price soar 7.58% during intraday trading on Monday, following a significant corporate announcement.The sharp increase is attributed to the company's...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"TLX.AU":"TELIX PHARMACEUTICALS LTD"},"translate_title":"个股追踪|再生元重大合作交易Telix制药盘中大涨7.58%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TLX.AU":1},"content_text":"TELIX PHARMACEUTICALS LTD (TLX.AU) saw its stock price soar 7.58% during intraday trading on Monday, following a significant corporate announcement.The sharp increase is attributed to the company's newly announced strategic collaboration with leading biotechnology firm Regeneron Pharmaceuticals. The agreement focuses on the co-development and co-commercialization of next-generation radiopharmaceutical therapies for oncology.Under the terms of the deal, Telix will receive an upfront cash payment of US$40 million and is eligible for potential development and commercial milestone payments of up to US$2.1 billion, plus royalties on future net sales. The collaboration combines Telix's radiopharmaceutical development platform and manufacturing capabilities with Regeneron's extensive biologics expertise and antibody discovery technologies, operating on a 50/50 cost and profit-sharing model for initial programs.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}